These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10579848)

  • 41. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
    Gangjee A; Namjoshi OA; Raghavan S; Queener SF; Kisliuk RL; Cody V
    J Med Chem; 2013 Jun; 56(11):4422-41. PubMed ID: 23627352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
    Chan DC; Laughton CA; Queener SF; Stevens MF
    J Med Chem; 2001 Aug; 44(16):2555-64. PubMed ID: 11472209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
    Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
    J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
    Gangjee A; Lin X
    J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
    Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
    J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine.
    Rosowsky A; Queener SF; Cody V
    Drug Des Discov; 1999 Jul; 16(1):25-40. PubMed ID: 10466054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural studies on bioactive compounds. 30. Crystal structure and molecular modeling studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate.
    Cody V; Chan D; Galitsky N; Rak D; Luft JR; Pangborn W; Queener SF; Laughton CA; Stevens MF
    Biochemistry; 2000 Apr; 39(13):3556-64. PubMed ID: 10736154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural studies on bioactive compounds. Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii.
    Chan DC; Laughton CA; Queener SF; Stevens MF
    Bioorg Med Chem; 2002 Sep; 10(9):3001-10. PubMed ID: 12110323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of molecular modelling studies of dihydrofolate reductase inhibitors against opportunistic microorganisms and comprehensive evaluation of new models.
    Tawari NR; Bag S; Degani MS
    Curr Pharm Des; 2011; 17(7):712-51. PubMed ID: 21395543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes.
    Cody V; Pace J; Makin J; Piraino J; Queener SF; Rosowsky A
    Biochemistry; 2009 Mar; 48(8):1702-11. PubMed ID: 19196009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis.
    Mattioni BE; Jurs PC
    J Mol Graph Model; 2003 Mar; 21(5):391-419. PubMed ID: 12543137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
    Gangjee A; Vidwans A; Elzein E; McGuire JJ; Queener SF; Kisliuk RL
    J Med Chem; 2001 Jun; 44(12):1993-2003. PubMed ID: 11384244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Classical and nonclassical furo[2,3-d]pyrimidines as novel antifolates: synthesis and biological activities.
    Gangjee A; Devraj R; McGuire JJ; Kisliuk RL; Queener SF; Barrows LR
    J Med Chem; 1994 Apr; 37(8):1169-76. PubMed ID: 8164259
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.
    Bartlett MS; Shaw M; Navaran P; Smith JW; Queener SF
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2436-41. PubMed ID: 8585722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
    Gangjee A; Zeng Y; Talreja T; McGuire JJ; Kisliuk RL; Queener SF
    J Med Chem; 2007 Jun; 50(13):3046-53. PubMed ID: 17552508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
    Nelson RG; Rosowsky A
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.